Back to Search Results
Back to Results
Melanoma / Skin
General Information
Study Name:
Propel: A Phase 1B, open-label, multicenter study to investigate the safety and preliminary efficacy of NKTR-214 in combination with Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in patients with locally advanced or metastatic solid tumors
Age Group:
Adult
Protocol Number:
NCT03138889
Background Information:
The purpose of this study is to test the safety, tolerability, and effectiveness of NKTR-214 given in combination with KEYTRUDA®
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
Male/female participants with histologically confirmed locally advanced or metastatic melanoma (pembrolizumab only), locally advanced or metastatic urothelial carcinoma (atezolizumab only), or metastatic NSCLC (pembrolizumab only)
Additional eligibility in protocol
Ineligibility Information
Participants who have active or stable brain metastases or who have a history of brain metastases
Prior malignancy treated with anticancer therapy (including systemic chemotherapy, radiation and/or surgery) within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Additional ineligibility in protocol
Contact Information
Contact Name:
Kelly Jeffords, CCRP
Contact Phone:
571-472-0631
Contact Email:
kelly.jeffords@inova.org